期刊文献+

乳腺癌患者血清GSN与ORM1差异表达与化疗耐药相关性初步研究 被引量:3

Relationship on the difference expression of gelsolin precursor,alpha-1-acid glycoprotein 1 precursor and chemotherapy drug resistance in breast cancer
原文传递
导出
摘要 目的:通过检测局部晚期乳腺癌患者新辅助化疗前后的血清凝溶胶蛋白前体(gelsolin,GSN)和α-1-酸性糖蛋白1前体(alpha-1-acid glycoprotein 1precursor,ORM1)变化,从蛋白质组学的角度探索乳腺癌的化疗耐药机制并寻找一种能够评价乳腺癌化疗耐药性的血清蛋白标志。方法:选取烟台毓璜顶医院肿瘤内科2008-01-01-2010-01-01接受新辅助化疗的局部晚期乳腺癌患者共30例,根据化疗疗效分为敏感组和耐药组。耐药组6例,敏感组24例。留取化疗前后血清进行双向凝胶电泳,得到化疗前后在耐药组血清中特异表达的差异蛋白质点,应用基质辅助激光解析电离飞行时间质谱(MALDI-TOF-TOF)技术对获得的差异蛋白质胶点进行质谱鉴定,得到耐药组的差异蛋白,应用蛋白质印迹法验证差异蛋白的变化趋势。结果:从耐药组血清中共筛选、鉴定出13个差异蛋白质,上调蛋白7个,下调蛋白6个。其中GSN化疗后下调,ORM1化疗后上调。应用蛋白质印迹法验证,结果显示这2个蛋白的变化与其在蛋白质组学中的表现一致。结论:乳腺癌耐药组患者化疗后血清GSN下调,ORM1上调,这2个蛋白可能与乳腺癌化疗耐药机制有关,可能作为评价乳腺癌化疗耐药性的血清标志。 OBJECTIVE: To detect the changes in protein of breast cancer before and after the neoadjuvant chemotherapy,so as to explore the mechanism of breast cancer chemotherapy drug resistance by proteomics and to find serum protein marker of breast cancer to evaluate the chemotherapy drug resistance. METHODS: The data of 30 locally advanced breast cancer patients who had accepted neoadjuvant chemotherapy was collected between 1st. January 2008 and 1st. January 2010,in Department of Oncology Yantai Yuhuangding Hospital. The patients were divided into resistant and sensitive groups according to the curative effect of chemotherapy. Resistant group were 6 cases and sensitive group 24 cases. Fasting serum specimens were obtained before and after the chemotherapy. Two way gel electrophoresis was used to get the gel maps of the serum specimens and gel analysis software was used to analysis the image maps, screen the protein points which differentially expressed before and after chemotherapy. Serum protein were identified in the way of matrix auxiliary laser disintegrate series time of flight mass spectrometer (MALDI-TOF TOF) technology for the protein glue points. RESULTS: Thirteen differences protein were obtained from the serum of resistant group in breast cancer. Among them, seven were upregulated proteins,six were downregulated proteins. Ggelsolin Precursor was downregulated and Alpha-1 acid glycoprotein 1 precursor was upregulated after neoadjuvant chemotherapy in resistance group. Western imprinting method was used to test the variation trend before and after chemotherapy. The variation trend of western imprinting method and the proteomics results were consistent. CONCLUSIONS:Gelsolin Precursor was downregulated and Alpha-l-acid glycoprotein 1 precursor was upregulated after neoadjuvant chemotherapy in resistance group. The two proteins may be associated with breast cancer chemotherapy drug resistance mechanism and may be as the serum markers to evaluate the chemotherapy drug resistance in breast cancer.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第12期920-924,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 山东省自然基金(Y2006C108) 烟台市科学技术计划(2006131-2)
关键词 蛋白质组学 乳腺肿瘤 化疗耐药性 凝溶胶蛋白 a-1-酸性糖蛋白 proteomics breast neoplasms chemotherapy drug resistance gelsolin alpha-l-acid glycoprotein
  • 相关文献

参考文献16

二级参考文献83

  • 1陈智伟,廖美琳,陈玉蓉,赵家美,张心敏,成柏君.WHO标准和RECIST标准评价肺癌化疗疗效的比较[J].循证医学,2004,4(2):83-84. 被引量:36
  • 2沈镇宙,柳光宇,苏逢锡,何萍青,杨名添,施俊义,盛援,邹强,李亚芬.多西紫杉醇加表柔比星治疗局部晚期乳腺癌的多中心Ⅱ期临床研究[J].中华肿瘤杂志,2005,27(2):126-128. 被引量:56
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:167
  • 4倪晓光,赵平.凝溶胶蛋白的结构和功能及其抑制肿瘤的作用[J].实用癌症杂志,2007,22(1):105-107. 被引量:5
  • 5Trudeau M, Sinclair SE, Clemons M. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review [J]. Cancer Treat Rev, 2005, 31 (4) : 283-302.
  • 6Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 [J]. J Natl Caner Inst Monogr, 2001, (30): 96-102.
  • 7Bear HD, Anderson S, Brow A, et al. National surgical adjuvant breast and bowel project protocol B-27: The effect on tumor response of adding sequential preoperative docetaxel to preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Onol , 2003, 21(22): 4165- 4174.
  • 8Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocol B-18 and B-27 [J ]. J Clin Oncol, 2008, 26(5): 778-785.
  • 9Perou CM, Serlie T, Eisen MB, et al. Molecular portraits of human breast tumors [ J ]. Nature, 2000, 406 (6797) : 747-752.
  • 10Carey LA, Dees EC, Sawyer L, et al. The triple nagetive paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, 13 (8) : 2329-2334.

共引文献1890

同被引文献35

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部